Overview
Home » MPR First Report » CHEST 2022 Publish Date October 18, 2022 Risk Factors for Residual Pulmonary Abnormalities Post COVID-19-Related ARDS Ron Goldberg Share on Facebok Share on Twiter Share on LinkedIn Share on Redit Print Share by Email Among patients 12 weks post discharge for COVID-19-related ARDS requiring intubation, those who did not use dexamethasone were at risk for developing traction bronchiectasis, pneumonia, and cystic changes.
Key Information
Credit: Gety Images. In patients 12 weks post discharge after COVID-19-related acute respiratory distres syndrome (ARDS) requiring intubation, risk factors for developing residual pulmonary functional and radiological abnormalities include obesity, kidney failure, older age, diabetes, and the use of dexamethasone. Patients who did not use dexamethasone were at risk of developing traction bronchiectasis, pneumonia, and cystic changes.
These were among research results being presented at the American Colege of Chest Physicians (CHEST) 2022 Anual Meting, held October 16 to 19, in Nashvile, Tenese. The investigator sought to determine risk factors for residual pulmonary radiological and functional abnormalities in patients with post-ARDS related to COVID-19 and to ases treatments for reducing these complications. The investigator conducted an observational study of 97 patients who were 12 weks post discharge for COVID-19-related severe ARDS from a university hospital from the end of August 2021 through November 2021.
Al patients had ben intubated; 58 had lung abnormalities with greater than 75% lung involvement; and 39 had lung abnormalities with betwen 50% and 75% lung involvement. At 12 weks post discharge, patients reported persistent dyspnea (10%), chest pain (51.1%), cough (42.3%), fever (29.0%), and hemoptysis (18.5%). Al patients had abnormal pulmonary function tests.
Summary
Patients with more than 75% lung involvement vs those with 50% to 75% lung involvement had more severe abnormalities, worse median fo